Valuation: Artivion, Inc.

Market Cap 1.27B 1.11B 1.04B 952M 1.79B 122B 1.81B 12.32B 4.81B 60B 4.76B 4.65B 207B P/E 2026 *
312x
P/E 2027 * 64x
Enterprise Value 1.27B 1.11B 1.04B 952M 1.79B 122B 1.81B 12.32B 4.81B 60B 4.76B 4.65B 207B EV / Sales 2026 *
2.61x
EV / Sales 2027 * 2.35x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day+3.24%
1 week+2.88%
Current month+16.15%
1 month+10.55%
3 months-29.52%
6 months-37.08%
Current year-42.78%
1 week 24.55
Extreme 24.55
26.38
1 month 21.3
Extreme 21.295
26.38
Current year 19.16
Extreme 19.16
46.84
1 year 19.16
Extreme 19.16
48.25
3 years 12.16
Extreme 12.1582
48.25
5 years 9.64
Extreme 9.64
48.25
10 years 9.64
Extreme 9.64
48.25
Manager TitleAgeSince
Chief Executive Officer 59 02/09/2014
Director of Finance/CFO 53 04/12/2023
Chief Tech/Sci/R&D Officer 56 01/06/2023
Director TitleAgeSince
Director/Board Member 71 01/12/2003
Director/Board Member 66 01/12/2003
Director/Board Member 61 01/05/2012
Date Insider Type Main position Quantity % Market Cap.
11/6/26 Fiscal year

General Counsel

132,003 0.2719%
2/6/26 Others

Director

-12,650 0.0261%
1/6/26 Other

General Counsel

104,260 0.2148%
Change 5-day change 1-year change 3-year change Capi.($)
+3.24%+2.88%-16.88%+54.71% 1.23B
+1.39%+2.78%-17.43%-7.24% 180B
+1.21%+1.12%-9.38%-4.85% 107B
+0.41%+2.36%+7.16%+66.10% 60.29B
-3.62%-6.37%+22.17%+49.73% 50.19B
+1.64%+2.87%-14.25%-43.96% 43.08B
+2.45%+2.11% - - 32.77B
+2.56%-3.07%-17.55%-43.28% 27.61B
+0.93%-5.98%+25.71%-6.66% 23.1B
+2.02%+1.83%-5.23%-4.95% 20.86B
Average +1.22%-1.16%-2.85%+6.62% 54.51B
Weighted average by Cap. +0.94%+0.26%-6.28%+2.70%

Financials

2026 *2027 *
Net sales 486M 427M 398M 365M 686M 46.63B 695M 4.73B 1.85B 23.02B 1.83B 1.79B 79.58B 540M 475M 442M 406M 762M 51.76B 772M 5.25B 2.05B 25.56B 2.03B 1.98B 88.35B
Net income 4.4M 3.87M 3.6M 3.31M 6.21M 422M 6.29M 42.8M 16.72M 208M 16.52M 16.16M 720M 22.59M 19.86M 18.48M 16.97M 31.87M 2.17B 32.29M 220M 85.81M 1.07B 84.79M 82.96M 3.7B
Net Debt - -
Logo Artivion, Inc.
Artivion, Inc. is a medical device company focused on developing solutions that address cardiac and vascular surgeons in treating patients with aortic diseases. The Company operates through two segments, which include Medical Devices and Preservation Services. The Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other products. The Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. It has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products. It is engaged in the endovascular repair of aortic arch disease and the developer of the NEXUS Aortic Arch System.
Employees
1,800
Date Price Change Volume
27/07/26 US$26.10 +3.24% 427,597
24/07/26 US$25.28 +1.12% 370,249
23/07/26 US$25.00 -0.56% 585,584
22/07/26 US$25.14 +0.80% 422,282
21/07/26 US$24.94 -1.69% 535,361
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
26.10USD
Average target price
42.00USD
Spread / Average Target
+60.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AORT Stock